Deutsche Bank Maintains a 'Buy' on Dendreon (DNDN): Buyers on Any Weakness
Tweet
Share
E-mail
Get Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 47
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 47
Join SI Premium – FREE
Deutsche Bank maintains a 'Buy' on Dendreon (NASDAQ: DNDN) price target of $18.00.
Deutsche analyst said, "Johnson & Johnson (NYSE: JNJ) just announced that the Independent Data Monitoring Committee recommended the unblinding of the Zytiga pre-chemo prostate cancer ph 3 trial due to PFS & OS clinical benefit. Placebo patients are now recommended to take Zytiga. JNJ plans to file for FDA approval in H2:12. This is the same indication as Provenge."
"Our view is that hit on interim was expected by many investors. This is more of negative headline risk and we continue to believe current Provenge peak sales of $1.6B ($1.1B in US & $500M in EU) in 2020E are achievable. In our opinion, current DNDN stock price factors in $500M in peak Provenge sales. As per doctor checks, we believe Provenge and Zytiga will be sequenced and both will be used."
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.87 yesterday.
Deutsche analyst said, "Johnson & Johnson (NYSE: JNJ) just announced that the Independent Data Monitoring Committee recommended the unblinding of the Zytiga pre-chemo prostate cancer ph 3 trial due to PFS & OS clinical benefit. Placebo patients are now recommended to take Zytiga. JNJ plans to file for FDA approval in H2:12. This is the same indication as Provenge."
"Our view is that hit on interim was expected by many investors. This is more of negative headline risk and we continue to believe current Provenge peak sales of $1.6B ($1.1B in US & $500M in EU) in 2020E are achievable. In our opinion, current DNDN stock price factors in $500M in peak Provenge sales. As per doctor checks, we believe Provenge and Zytiga will be sequenced and both will be used."
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Honeywell International (HON) to Hold
- Deutsche Bank Starts Astera Labs (ALAB) at Buy
- Baird incrementally positive on new data from Biohaven Pharma (BHVN)
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
